SCHEMBL2374728

SCHEMBL2374728

C=C(C(=O)OC)N(Cc1ccc(-c2ccncc2)cc1)C(=O)C=Cc1ccc(C(F)(F)F)cc1

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
HTR5A P47898 2/20 0.41
NOS3 P29474 4/20 0.40
NOS1 P29475 4/20 0.40
NOS2 P35228 4/20 0.40
PPARD Q03181 3/20 0.39
PPARA Q07869 3/20 0.39
PPARG P37231 2/20 0.39
HDAC3 O15379 1/20 0.39
ADAM17 P78536 1/20 0.39
HDAC1 Q13547 1/20 0.39
HDAC2 Q92769 1/20 0.39
HDAC10 Q969S8 1/20 0.39
HDAC11 Q96DB2 1/20 0.39
HDAC8 Q9BY41 1/20 0.39
HDAC6 Q9UBN7 1/20 0.39
HDAC5 Q9UQL6 1/20 0.39
CYP1A2 P05177 1/20 0.38
MAOB P27338 2/20 0.38
CYP1A1 P04798 1/20 0.38
CYP1B1 Q16678 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2374727 1.00 HTR5A (0.41) HTR5ANOS3NOS1NOS2PPARD
SCHEMBL2376099 0.87 TRPV1 (0.43) HTR5ANOS3NOS1NOS2PPARD
SCHEMBL2376094 0.87 TRPV1 (0.43) HTR5ANOS3NOS1NOS2PPARD
SCHEMBL2375187 0.79 NOS3 (0.46) HTR5ANOS3NOS1NOS2PPARD
SCHEMBL2375182 0.79 NOS3 (0.46) HTR5ANOS3NOS1NOS2PPARD
SCHEMBL2375181 0.79 NOS3 (0.46) HTR5ANOS3NOS1NOS2PPARD
SCHEMBL2375206 0.78 NOS3 (0.46) HTR5ANOS3NOS1NOS2PPARD
SCHEMBL2375200 0.78 NOS3 (0.46) HTR5ANOS3NOS1NOS2PPARD
SCHEMBL2375197 0.78 NOS3 (0.46) HTR5ANOS3NOS1NOS2PPARD
SCHEMBL2374716 0.75 NOS3 (0.44) HTR5ANOS3NOS1NOS2PPARD

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS ACTELION PHARMACEUTICALS LTD. (CH) 2011-09-15 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224210-A1 NOVEL BIS-AMIDES AS ANTI-MALARIAL AGENTS CTSA, BECN1, HDAC6 HTR5A 4420/4885NOS3 783/4885NOS1 996/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.